US drugmakers rise after Trump announces Pfizer price cuts, promises more deals

Pfizer shares rose approximately 5% after the company agreed to cut prices on drugs sold to Medicaid and introduce new drugs at a "most favored nation" price, following a White House initiative. The drugmaker will also offer 40-85% discounts on select medications directly to consumers via the new TrumpRx website. This agreement, viewed by analysts as a potential precedent for other pharmaceutical companies, appears to mitigate broader sector concerns regarding more punitive MFN policies or tariffs, leading to gains across major pharma stocks.

Analysis

Pfizer (PFE.N) shares rallied approximately 5% following the announcement of a pricing agreement with the White House, which appears to resolve a significant regulatory overhang for the pharmaceutical sector. Under the deal, Pfizer will reduce prices for the Medicaid program, apply "most favored nation" pricing to new drugs, and sell select medications directly to consumers at discounts of 40-85% via a new government website. This agreement is the first of its kind after the administration's July mandate for price reductions, and the market's positive reaction extends to peers like Merck, Eli Lilly, and AbbVie, which saw gains of 3-5%. According to BMO Capital Markets, this development is viewed favorably as it likely establishes a precedent for other drugmakers that involves manageable price concessions rather than a more punitive, unilateral implementation of tariffs or broad MFN policies. The market's relief rally suggests investors perceive this negotiated outcome as a de-risking event for the industry.

Key Decisions for Investors

• Investors should re-evaluate Pfizer's valuation, as the stock's 5% rise indicates the market is pricing in a significant reduction in regulatory risk related to drug pricing mandates.
• Monitor other major pharmaceutical companies like Merck (MRK.N), Eli Lilly (LLY.N), and AbbVie (ABBV.N) for similar agreements, as Pfizer's deal is viewed as a template that could provide further positive catalysts for the sector.
• While the immediate reaction is positive, it is prudent to assess the long-term impact of these price concessions on Pfizer's margins and revenue from key drugs like Xeljanz in subsequent quarterly reports.